Pipeline: Expanding the Potential of Raviset®
Beyond Endometriosis: A Broader Vision for Women’s Health
Raviset® is not just a treatment; it represents a scalable platform for uterine disorders, including AUB, Dysmenorrhea, and other prevalent conditions that impact billions of women globally. Utilizing the FDA 505(b)(2) pathway, we have successfully demonstrated the efficacy of Raviset uterine therapy for these debilitating issues. We are actively working to expand its indications to encompass a broader spectrum of uterine disorders. By building on the proven success of our therapy, we aim to provide innovative, non-hormonal women’s health solutions that address several critical conditions affecting women’s health.
The 505(b)(2) Pathway
The Regulatory Shortcut
With regulatory approval for endometriosis, Foraviset plans to leverage the FDA 505(b)(2) pathway for future indications. This strategy enables us to capitalize on the existing safety data of Raviset®, thereby minimizing development time and costs. Our ultimate aim is to position Raviset® as a leading uterine therapy within our women's health solutions, addressing chronic uterine disorders effectively.
Raviset Uterine Disorders: Pipeline Innovations
Raviset® is not just a therapy; it represents a cornerstone in the paradigm shift for women’s health solutions. By broadening its indications to include these critical conditions, FORAVISET is utilizing the FDA 505(b)(2) pathway to advance its mission of providing safe, effective, and life-changing solutions for millions of women globally through Raviset uterine therapy.